Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IDYAthis companyIDEAYA Biosciences, Inc.	$31.52	-27.01×	2.99×	13.99×	-19.22×	-438.0%	-43.9%	-72.8%	-52.0%	-11.1%	-15.2%	-2.4%	0.03×	0.55×	0×	11.34×	0.0%	1	14.74	2	C
COGTCogent Biosciences, Inc.	$32.94	-17.41×	8.99×	0×	-17.61×	-99.0%	0.0%	0.0%	0.0%	-51.7%	-38.1%	-4.7%	0.4×	0.18×	-108.87×	14.23×	0.0%	2	7.51	1	C-
ERASErasca, Inc.	$15.04	-8.45×	3.24×	0×	-8.47×	-99.3%	0.0%	0.0%	0.0%	-38.3%	-35.3%	-9.1%	0.14×	0.22×	0×	10.04×	0.0%	1	35.36	1	C-
FHTXFoghorn Therapeutics Inc.	$2.01	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
NRIXNurix Therapeutics, Inc.	$16.09	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
PRLDPrelude Therapeutics Incorporated	$3.84	-2.25×	3.25×	18.38×	-1.48×	-2.4%	85.9%	-861.3%	-819.6%	-145.0%	-114.8%	-25.3%	0.26×	0.18×	0×	1.99×	0.0%	4	-3.06	2	C
Peer median	—	-5.54×	3.24×	11×	-5.2×	-99.3%	77.5%	-265.6%	-240.3%	-49.1%	-47.3%	-18.0%	0.14×	0.22×	0×	7.02×	0.0%	3	7.51	2	—